Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease - PubMed (original) (raw)
Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease
Chikkathur N Madhavarao et al. Proc Natl Acad Sci U S A. 2005.
Abstract
Canavan's disease (CD) is a fatal, hereditary disorder of CNS development that has been linked to mutations in the gene for the enzyme aspartoacylase (ASPA) (EC 3.5.1.15). ASPA acts to hydrolyze N-acetylaspartate (NAA) into l-aspartate and acetate, but the connection between ASPA deficiency and the failure of proper CNS development is unclear. We hypothesize that one function of ASPA is to provide acetate for the increased lipid synthesis that occurs during postnatal CNS myelination. The gene encoding ASPA has been inactivated in the mouse model of CD, and here we show significant decreases in the synthesis of six classes of myelin-associated lipids, as well as reduced acetate levels, in the brains of these mice at the time of peak postnatal CNS myelination. Analysis of the lipid content of white matter from a human CD patient showed decreased cerebroside and sulfatide relative to normal white matter. These results demonstrate that myelin lipid synthesis is significantly compromised in CD and provide direct evidence that defective myelin synthesis, resulting from a deficiency of NAA-derived acetate, is involved in the pathogenesis of CD.
Figures
Fig. 1.
ASPA (A) and NAA (B) immunoreactivity in the rat corpus callosum. Oligodendrocytes are arranged in rows within the corpus callosum and are strongly stained for ASPA but only weakly stained for NAA (arrows in B). Neurons, such as those in the cortex, are stained much more intensely for NAA than are oligodendrocytes. (Scale bar, 120 μm.)
Fig. 2.
Lipid analysis in CD and normal human cerebral white matter (WM). (A) Note the relative paucity of bands comigrating with the cerebroside standards (black arrows) and relative lack of the more mobile sulfatide fraction (white arrow) in the CD patient sample compared with the control. Lane 1, standards mix; lane 2, CD patient white matter lipids; lane 3, control human white matter lipids; lane 4, sulfatides; lane 5, cerebrocides. (B) Note the prominence of the bands (comigrating with cerebroside) in the control specimen and their reduction in the CD patient specimen (white arrows). Note also the prominence of anomalous lipid bands in the CD patient (black arrows).
Fig. 3.
Proposed model for NAA synthesis and degradation. See Discussion for details. OAA, oxaloacetic acid; α-KG, α-ketoglutarate; AAT, aspartate aminotransferase; GDH, glutamate dehydrogenase; PDH, pyruvate dehydrogenase; F.A., fatty acids; Ac-CoA, acetyl CoA.
Similar articles
- N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H, Wang-Eckhardt L, Hartmann D, Gieselmann V, Eckhardt M. Maier H, et al. J Neurosci. 2015 Oct 28;35(43):14501-16. doi: 10.1523/JNEUROSCI.1056-15.2015. J Neurosci. 2015. PMID: 26511242 Free PMC article. - Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM, Peethambaran A, Mathew R, Sambhu PA, Hershfield J, Moffett JR, Madhavarao CN. Namboodiri AM, et al. Mol Cell Endocrinol. 2006 Jun 27;252(1-2):216-23. doi: 10.1016/j.mce.2006.03.016. Epub 2006 May 2. Mol Cell Endocrinol. 2006. PMID: 16647192 Review. - Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M, Wollmann RL, Cerda SR, Dugas J, Barres BA, Popko B. Traka M, et al. J Neurosci. 2008 Nov 5;28(45):11537-49. doi: 10.1523/JNEUROSCI.1490-08.2008. J Neurosci. 2008. PMID: 18987190 Free PMC article. - Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M, Leichtlein CB, Symes CW, Serikawa T, Young D, During MJ. Klugmann M, et al. Mol Ther. 2005 May;11(5):745-53. doi: 10.1016/j.ymthe.2005.01.006. Mol Ther. 2005. PMID: 15851013 - Molecular basis of Canavan's disease: from human to mouse.
Surendran S, Matalon KM, Tyring SK, Matalon R. Surendran S, et al. J Child Neurol. 2003 Sep;18(9):604-10. doi: 10.1177/08830738030180090601. J Child Neurol. 2003. PMID: 14572138 Review.
Cited by
- Diagnosing Parkinson's disease and monitoring its progression: Biomarkers from combined GC-TOF MS and LC-MS/MS untargeted metabolomics.
Dahabiyeh LA, Nimer RM, Wells JD, Abu-Rish EY, Fiehn O. Dahabiyeh LA, et al. Heliyon. 2024 Apr 27;10(9):e30452. doi: 10.1016/j.heliyon.2024.e30452. eCollection 2024 May 15. Heliyon. 2024. PMID: 38720721 Free PMC article. - Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.
Grønbæk-Thygesen M, Hartmann-Petersen R. Grønbæk-Thygesen M, et al. Cell Biosci. 2024 Apr 6;14(1):45. doi: 10.1186/s13578-024-01224-6. Cell Biosci. 2024. PMID: 38582917 Free PMC article. Review. - The developmental trajectory of 1H-MRS brain metabolites from childhood to adulthood.
Thomson AR, Hwa H, Pasanta D, Hopwood B, Powell HJ, Lawrence R, Tabuenca ZG, Arichi T, Edden RAE, Chai X, Puts NA. Thomson AR, et al. Cereb Cortex. 2024 Mar 1;34(3):bhae046. doi: 10.1093/cercor/bhae046. Cereb Cortex. 2024. PMID: 38430105 Free PMC article. - Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis.
Murthy D, Attri KS, Shukla SK, Thakur R, Chaika NV, He C, Wang D, Jha K, Dasgupta A, King RJ, Mulder SE, Souchek J, Gebregiworgis T, Rai V, Patel R, Hu T, Rana S, Kollala SS, Pacheco C, Grandgenett PM, Yu F, Kumar V, Lazenby AJ, Black AR, Ulhannan S, Jain A, Edil BH, Klinkebiel DL, Powers R, Natarajan A, Hollingsworth MA, Mehla K, Ly Q, Chaudhary S, Hwang RF, Wellen KE, Singh PK. Murthy D, et al. Nat Cell Biol. 2024 Apr;26(4):613-627. doi: 10.1038/s41556-024-01372-4. Epub 2024 Mar 1. Nat Cell Biol. 2024. PMID: 38429478 Free PMC article. - Developing a human iPSC-derived three-dimensional myelin spheroid platform for modeling myelin diseases.
Feng L, Chao J, Zhang M, Pacquing E, Hu W, Shi Y. Feng L, et al. iScience. 2023 Sep 25;26(11):108037. doi: 10.1016/j.isci.2023.108037. eCollection 2023 Nov 17. iScience. 2023. PMID: 37867939 Free PMC article.
References
- Frahm, J., Bruhn, H., Gyngell, M. L., Merboldt, K. D., Hanicke, W. & Sauter, R. (1989) Magn. Reson. Med. 11, 47–63. - PubMed
- Madhavarao, C. N., Chinopoulos, C., Chandrasekaran, K. & Namboodiri, M. A. (2003) J. Neurochem. 86, 824–835. - PubMed
- Moffett, J. R., Namboodiri, M. A. & Neale, J. H. (1993) J. Histochem. Cytochem. 41, 559–570. - PubMed
- Madhavarao, C. N., Moffett, J. R., Moore, R. A., Viola, R. E., Namboodiri, M. A. & Jacobowitz, D. M. (2004) J. Comp. Neurol. 472, 318–329. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases